Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Arcus Biosciences Announces New Employment Inducement Grants


Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company's common stock at an exercise price per share of $18.66, which was the closing price on September 25, 2023, and restricted stock units to acquire a total of 16,600 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2?. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com.

Inducement PR

Source: Arcus Biosciences


These press releases may also interest you

at 11:13
"Climate change is affecting human health around the globe. From extreme weather events to the spread of infectious diseases, we are seeing the consequences of the changing climate every day. As we face the challenge of climate change, strong and...

at 09:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day. The webcast event will be hosted by IDEAYA on Monday, December 4,...

at 06:32
The draw has been made: Since yesterday evening, it is clear who will face whom in the group stage of UEFA EURO 2024. The Final Draw for the European Football Championship took place in the Elbphilharmonie Concert Hall, Hamburg - and impressively in...

2 déc 2023
From November 27 to December 1, a group made up of more than 60 reporters, overseas communication officers, and social media personalities got their chance to witness the development of the Hainan Free Trade Port (FTP) up close, as they visited key...

2 déc 2023
From November 27 to December 1, a group made up of more than 60 reporters, overseas communication officers, and social media personalities got their chance to witness the development of the Hainan Free Trade Port (FTP) up close, as they visited key...

2 déc 2023
Bahrain has become the second country in the world and the first in the Middle East to approve the use of CASGEVY (exagamglogene autotemcel) for the treatment of patients with sickle cell disease and transfusion-dependent beta-thalassemia. The...



News published on and distributed by: